BioPharm International

BioPharm International magazine combines the scientific and business aspects of biopharmaceutical research, development, and production. We offer hands-on, peer-reviewed technical insights designed to help biopharmaceutical experts work more efficiently in their roles.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#954352

United States

#514712

Science and Education/Biology

#1228

Traffic sources

Monthly visitors

Articles

VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies

1 day ago | biopharminternational.com | Feliza Mirasol

On April 23, 2025, VERAXA Biotech (VERAXA), a Switzerland-based biotech company specializing in designing novel cancer therapies, announced that it has entered into a definitive agreement with Voyager Acquisition, a US-headquartered special purpose acquisition company focused on the healthcare sector, to create a combined business.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides

6 days ago | biopharminternational.com | Feliza Mirasol

A research team from Tokyo University of Science (TUS) explained in March 2025 that it is exploring ways to improve the delivery of antisense oligonucleotides (ASOs), a class of gene-targeting drugs, to the brain and other organs (1). Led by Professor Makiya Nishikawa, the team is following sustainable development goals (SDGs) put forth by the United Nations (2), particularly improving good health and well-being (SDG 3) and promoting industry, innovation, and infrastructure (SDG 9).
Cellino Partners with Karis Bio for Autologous iPSC Therapy to Treat Cardiovascular Disease

6 days ago | biopharminternational.com | Feliza Mirasol

On Apr 15, 2025, US-based Cellino, a biotechnology company specializing in autonomous biomanufacturing for personalized regenerative medicine, announced a strategic collaboration with South Korea-based Karis Bio, a cell therapy biotech. Through the partnership, the companies aim to industrialize a clinical-stage autologous induced pluripotent stem cell (iPSC)-derived cell therapy, the world’s first, according to the companies, for treating peripheral artery disease and coronary artery disease.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market

1 week ago | biopharminternational.com | Feliza Mirasol

Teva Pharmaceuticals, a United States-based affiliate of Teva Pharmaceutical Industries, and Samsung Bioepis launched eculizumab-aagh (under the brand name EPYSQLI), a biosimilar referencing eculizumab (brand name Soliris), in the US in April 2025.
Industry Outlook 2025: Talent Up for Grabs

1 week ago | biopharminternational.com | Felicity Thomas |Susan Haigney

The post-COVID-19 era has seen the consequences of ambitious programs launched during the pandemic, according to Erik Wiklund, CEO of Circio, such as a lack of capital for small biotech and employee layoffs, and Wiklund sees this impacting the industry during 2025. “Many companies launch great ambitions, large valuations.
FDA Approves Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

1 week ago | biopharminternational.com | Susan Haigney

Bristol Myers Squibb (BMS) announced on April 11, 2025 that FDA has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for unresectable or metastatic hepatocellular carcinoma (HCC). According to BMS, HCC is the most common primary liver cancer. The approval was based on results from the global Phase III randomized, open-label CheckMate-9DW trial.
Industry Outlook 2025: Cell Therapy Advancement

1 week ago | biopharminternational.com | Felicity Thomas |Susan Haigney

Edwin Stone, CEO of Cellular Origins, sees two themes having the biggest impact to the bio/pharma industry: the expansion of glucagon-like peptide-1 (GLP-1) and the growth of cell therapies from fourth- and third-line treatments to second-line treatments. “It really opens up that question of, when do we start to see first line treatments? And of course, part of that comes down to not just the safety and efficacy profiles, but the cost of goods, which still no one has a good answer to,” Stone says.
INTERPHEX 2025: The Challenge of Developing Ultra-Rare Disease Treatments

1 week ago | biopharminternational.com | Susan Haigney

Editor's note: this interview was originallypublished on PharmTech.com. Joe Katakowski, director of Research at the RTW Foundation, and Deanna Portero vice-president, Partnerships & Innovation, Orphan Therapeutics Accelerator, gave a presentation titled, “A Novel Pathway for Ultra-Rare Disease Treatment Development, Commercialization and Access”, at INTERPHEX 2025, which was held in New York City from April 1–3.
Tariff Pause Reinforces Uncertainty Among Biopharma Professionals

2 weeks ago | biopharminternational.com | Patrick Lavery

As Pharmaceutical Technology® Group was busy networking with industry leaders at INTERPHEX 2025 in New York City on April 2, United States President Donald Trump scheduled the announcement of what he called “Liberation Day” with a 10% baseline tariff on imported goods from most other countries in the world, effective April 5 (1).
Entos Collaborates with Circio to Develop In-Vivo Delivery of DNA Vectors

2 weeks ago | biopharminternational.com | Feliza Mirasol

UK-based Entos Pharmaceuticals (Entos), a clinical-stage genetic medicines company, has entered into a research collaboration with Norway-based Circio Holding, a biotechnology company specializing in circular RNA technology for next-generation nucleic acid medicines, under which Entos will develop and validate proteolipid vehicle (PLV) formulations of Circio´s circular RNA expression vectors (circVec) DNA vectors.